Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting
Oral Presentation Details
Presentation Title: Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL (Abstract #471)
Session Title: 704. Cellular Immunotherapies: Cellular Therapies for ALL
Session Date/Time: Sunday, December 12, 2021,
Presenting Author: Dr.
Location: Georgia World Congress Center, B401-B402 and virtual
The abstract is available on the
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.
View original content to download multimedia:https://www.prnewswire.com/news-releases/marker-therapeutics-announces-that-data-from-investigator-sponsored-phase-1-study-with-its-multitaa-specific-t-cells-to-be-presented-at-the-2021-american-society-of-hematology-annual-meeting-301428592.html
Investors: Solebury Trout, Xuan Yang, (646) 378-2975, email@example.com; Media: Solebury Trout, Amy Bonanno, (914) 450-0349, firstname.lastname@example.org